Steven Cohen Cogent Biosciences, Inc. Transaction History
Point72 Asset Management, L.P.
- $36 Billion
- Q2 2024
A detailed history of Steven Cohen (Point72 Asset Management, L.P.) transactions in Cogent Biosciences, Inc. stock. As of the latest transaction made, Point72 Asset Management, L.P. holds 10,470,398 shares of COGT stock, worth $114 Million. This represents 0.24% of its overall portfolio holdings.
Number of Shares
10,470,398
Previous 10,470,398
-0.0%
Holding current value
$114 Million
Previous $88.3 Million
-0.0%
% of portfolio
0.24%
Previous 0.24%
Shares
15 transactions
Others Institutions Holding COGT
# of Institutions
159Shares Held
114MCall Options Held
104KPut Options Held
163K-
Commodore Capital LP New York, NY9.74MShares$106 Million7.36% of portfolio
-
Kynam Capital Management, LP Princeton, NJ9.26MShares$101 Million6.08% of portfolio
-
Black Rock Inc. New York, NY7.29MShares$79.4 Million0.0% of portfolio
-
Tcg Crossover Management, LLC Palo Alto, CA6.96MShares$75.9 Million8.79% of portfolio
-
Fairmount Funds Management LLC Philadelphia, PA6.23MShares$67.9 Million10.42% of portfolio
About Cogent Biosciences, Inc.
- Ticker COGT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 65,758,300
- Market Cap $717M
- Description
- Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes CGT9486, a selective tyrosine kinase inhibitor designed to inhibit the KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found ...